Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT04840784 : A Phase 1a/1b Dose Escalation and Dose Expansion, First-in-human, Open-Labeled Study of ETH-155008 in Subjects With Relapsed or Refractory B-cell NHL, CLL/SLL and AML

Male or<br/>FemaleGender Male or

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18-80Age 18-80

Blood<br/>CancersCancer LocationBlood

Systemic therapy | Blood / Myeloma / LymphomaAcute Myeloid Leukaemia,B-Cell Non Hodgkin Lymphoma,Chronic Lymphocytic Leukaemia,Leukaemia,Lymphoma

Trial Overview Read MoreRead more

This phase I trial is trying to determine the recommended dose level, and understand how safe and effective, a new targeted therapy (ETH-155008) is in people with relapsed or refractory B-cell Non-Hodgkin's Lymphoma, chronic lymphocytic leukaemia, small lymphocytic lymphoma and acute myeloid leukaemia.

This trial is treating patients with B-cell Non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukaemia/ Small lymphocytic lymphoma (CLL/SLL) and acute myeloid leukaemia (AML)..

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1a/1b Dose Escalation and Dose Expansion, First-in-human, Open-Labeled Study of ETH-155008 in Subjects With Relapsed or Refractory B-cell NHL, CLL/SLL and AML

Commercial Sponsor

Shengke Pharmaceuticals Pty Ltd


This study will be conducted in 2 parts: dose escalation (Part 1) and cohort expansion (Part 2). In the dose escalation phase, ETH-155008 will be administered orally, once daily (QD) for 28 days at 6 dose levels ranging from 10mg to 100mg in 28-day cycles. Dose-limiting toxicity (DLT) will be assessed during the first treatment cycle and the maximum tolerated dose (MTD) will be identified. Additional participants will be treated in the dose expansion at the recommended phase 2 dose (RP2D).

Recruiting Hospitals Read MoreRead more

Alfred Hospital, Malignant Haematology & Stem Cell Transplantation Service
Ms Nola Kennedy
03 9076 2217

Epworth Hospital Haematology
East Melbourne
Dr Connie Barlas
03 9516 2374

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.